AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

A is -NH-, -N(C_1-C_6)alkyl-, or -N-(O-C_1-C_6 alkyl)-;

R_1 is -halo, -CH_3, -NO_2, -CN, -OH, -OCH_3, -NH_2, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each R_2 is independently:

(a) -halo, -OH, or -NH_2;

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, -NO_2, or -NH_2;

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

R_4 is:

(a) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(b) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_5 is independently -CN, -OH, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -halo, -N_3, -NO_2, -$N(R_7)_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_6 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -$N(R_7)_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_7 is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2; and

m is an integer ranging from 0 to 2.

2. (original) The compound of claim 1, wherein:

n is 0;

m is 0; and

R_4 is phenyl.

3. (original) The compound of claim 2, wherein the R_4 phenyl is unsubstituted.

4. (original) The compound of claim 2, wherein the R_4 phenyl is substituted at the 4-position.

5. (original) The compound of claim 4, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

6. (original) The compound of claim 5, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

7. (original) The compound of claim 5, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

8. (original) The compound of claim 4, wherein the R_4 phenyl is substituted with a -CF_3 group.

9. (original) The compound of claim 4, wherein the R_4 phenyl is substituted with a -OCF_3 group.

10. (original) The compound of claim 1, wherein:

n is 0;

m is 1;

R_3 is methyl; and

R_4 is phenyl.

11. (original) The compound of claim 10, wherein the R_4 phenyl is unsubstituted.

12. (original) The compound of claim 10, wherein the R_4 phenyl is substituted at the 4-position.

13. (original) The compound of claim 12, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

14. (original) The compound of claim 13, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

15. (original) The compound of claim 13, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

16. (currently amended) The compound of claim 12, wherein the $\underline{R_4}$ phenyl is substituted with a -CF_3 group.

17. (currently amended) The compound of claim 12, wherein the $\underline{R_4}$ phenyl is substituted with a -OCF_3 group.

18. (original) The compound of claim 1, wherein A is -NH-.

19. (original) The compound of claim 1, wherein A is -N(C_1-C_6)alkyl-.

20. (original) The compound of claim 1, wherein A is -N-(O-C_1-C_6 alkyl)-.

21. (currently amended) A compound of formula (II):



(II)

or a pharmaceutically acceptable salt thereof, wherein:

A is -N(O-C_1-C_6 alkyl)-, -CH_2-, -CH_2CH_2-, or -CH=CH-;

R_1 is -halo, -CH_3, -NO_2, -CN, -OH, -OCH_3, -NH_2, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each R_2 is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$;

(b) $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_8-C_{14})$tricycloalkyl, $-(C_5-C_{10})$cycloalkenyl, $-(C_8-C_{14})$bicycloalkenyl, $-(C_8-C_{14})$tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})$aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$;

(b) $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_8-C_{14})$tricycloalkyl, $-(C_5-C_{10})$cycloalkenyl, $-(C_8-C_{14})$bicycloalkenyl, $-(C_8-C_{14})$tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})$aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

R_4 is:

(a) $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_8-C_{14})$tricycloalkyl, $-(C_5-C_{10})$cycloalkenyl, $-(C_8-C_{14})$bicycloalkenyl, $-(C_8-C_{14})$tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(b) -phenyl, -naphthyl, $-(C_{14})$aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_5 is independently -CN, -OH, $-(C_1-C_6)$alkyl, $-(C_2-C_6)$alkenyl, -halo, $-N_3$, $-NO_2$, $-N(R_7)_2$, $-CH{=}NR_7$, $-NR_7OH$, $-OR_7$, $-COR_7$, $-C(O)OR_7$, $-OC(O)R_7$, $-OC(O)OR_7$, $-SR_7$, $-S(O)R_7$, or $-S(O)_2R_7$;

each R_6 is independently $-(C_1-C_6)$alkyl, $-(C_2-C_6)$alkenyl, $-(C_2-C_6)$alkynyl, $-(C_3-C_8)$cycloalkyl, $-(C_5-C_8)$cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, $-C(halo)_3$, $-CH(halo)_2$, $-CH_2(halo)$, -CN, -OH, -halo, $-N_3$, $-NO_2$, $-N(R_7)_2$, $-CH{=}NR_7$, $-NR_7OH$, $-OR_7$, $-COR_7$, $-C(O)OR_7$, $-OC(O)R_7$, $-OC(O)OR_7$, $-SR_7$, $-S(O)R_7$, or $-S(O)_2R_7$;

each R_7 is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$ or -CH_2(halo);

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2; and

m is an integer ranging from 0 to 2.

22. (original) The compound of claim 21, wherein:

n is 0;

m is 0; and

R_4 is phenyl.

23. (original) The compound of claim 22, wherein the R_4 phenyl is unsubstituted.

24. (original) The compound of claim 22, wherein the R_4 phenyl is substituted at the 4-position.

25. (original) The compound of claim 24, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

26. (original) The compound of claim 25, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

27. (original) The compound of claim 25, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

28. (original) The compound of claim 24, wherein the R_4 phenyl is substituted with a -CF_3 group.

29. (original) The compound of claim 24, wherein the R_4 phenyl is substituted with a -OCF_3 group.

30. (original) The compound of claim 21, wherein:

n is 0;

m is 1;

R_3 is methyl; and

R_4 is phenyl.

31. (original) The compound of claim 30, wherein the R_4 phenyl is unsubstituted.

32. (original) The compound of claim 30, wherein the R_4 phenyl is substituted at the 4-position.

33. (original) The compound of claim 32, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

34. (original) The compound of claim 33, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

35. (original) The compound of claim 33, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

36. (original) The compound of claim 32, wherein the R_4 phenyl is substituted with a -CF_3 group.

37. (original) The compound of claim 32, wherein the R_4 phenyl is substituted with a -OCF_3 group.

38. (original) The compound of claim 21, wherein A is -N(O-C_1-C_6 alkyl)-.

39. (original) The compound of claim 21, wherein A is -CH_2-.

40. (original) The compound of claim 21, wherein A is -CH_2CH_2-.

41. (original) The compound of claim 21, wherein A is -CH=CH-.

42. (currently amended) A compound of formula (III):



(III)

or a pharmaceutically acceptable salt thereof, wherein:

A is -NH- or ~~-N(C_1-C_6 alkyl)-~~ -N(C_1-C_6)alkyl-;

R_1 is -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each R_2 is independently:

(a) -halo, -OH, or $-NH_2$;

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$;

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

R_4 is:

(a) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(b) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_5 is independently -CN, -OH, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -halo, -N_3, -NO_2, -$N(R_7)_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_6 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -$N(R_7)_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_7 is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2; and

m is an integer ranging from 0 to 2.

43. (original) The compound of claim 42, wherein:

n is 0;

m is 0; and

R_4 is phenyl.

44. (original) The compound of claim 43, wherein the R_4 phenyl is unsubstituted.

45. (original) The compound of claim 43, wherein the R_4 phenyl is substituted at the 4-position.

46. (original) The compound of claim 45, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

47. (original) The compound of claim 46, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

48. (original) The compound of claim 46, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

49. (original) The compound of claim 45, wherein the R_4 phenyl is substituted with a -CF_3 group.

50. (original) The compound of claim 45, wherein the R_4 phenyl is substituted with a -OCF_3 group.

51. (original) The compound of claim 42, wherein:

n is 0;

m is 1;

R_3 is methyl; and

R_4 is phenyl.

52. (original) The compound of claim 51, wherein the R_4 phenyl is unsubstituted.

53. (original) The compound of claim 51, wherein the R_4 phenyl is substituted at the 4-position.

54. (original) The compound of claim 53, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

55. (original) The compound of claim 54, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

56. (original) The compound of claim 54, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

57. (original) The compound of claim 53, wherein the R_4 phenyl is substituted with a -CF_3 group.

58. (original) The compound of claim 53, wherein the R_4 phenyl is substituted with a $-OCF_3$ group.

59. (original) The compound of claim 42, wherein A is -NH-.

60. (currently amended) The compound of claim 42, wherein A is ~~-N(C_1-C_6 alkyl)-~~ -N(C_1-C_6)alkyl-.

61. (original) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

62. (original) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21 and a pharmaceutically acceptable carrier or excipient.

63. (original) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42 and a pharmaceutically acceptable carrier or excipient.

64. (original) A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

65. (original) A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

66. (original) A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

67. (original) A method for treating urinary incontinence in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

68. (original) A method for treating urinary incontinence in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

69. (original) A method for treating urinary incontinence in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

70. (original) A method for treating an ulcer in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

71. (original) A method for treating an ulcer in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

72. (original) A method for treating an ulcer in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

73. (original) A method for treating irritable-bowel syndrome in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

74. (original) A method for treating irritable-bowel syndrome in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

75. (original) A method for treating irritable-bowel syndrome in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

76. (original) A method for treating inflammatory-bowel disease in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

77. (original) A method for treating inflammatory-bowel disease in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

78. (original) A method for treating inflammatory-bowel disease in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

79. (original) A method for inhibiting VR1 function in a cell comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

80. (original) A method for inhibiting VR1 function in a cell comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

81. (original) A method for inhibiting VR1 function in a cell comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

82. (original) A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.

83. (original) A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 21.

84. (original) A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 42.

85. (original) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

86. (original) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 21 and a pharmaceutically acceptable carrier or excipient.

87. (original) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 42 and a pharmaceutically acceptable carrier or excipient.

88. (currently amended) A compound of formula (IV):



(IV)

or a pharmaceutically acceptable salt thereof, wherein:

Ar_2 is



,


,


,


,



,


,


,


,



,


, or


;

R_1 is -H, -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each R_2 is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$;

(b) $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_8-C_{14})$tricycloalkyl, $-(C_5-C_{10})$cycloalkenyl, $-(C_8-C_{14})$bicycloalkenyl, $-(C_8-C_{14})$tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})$aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$;

(b) $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_8-C_{14})$tricycloalkyl, $-(C_5-C_{10})$cycloalkenyl, $-(C_8-C_{14})$bicycloalkenyl, $-(C_8-C_{14})$tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_5 is independently -CN, -OH, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -halo, -N_3, -NO_2, -$N(R_7)_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_6 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_7 is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each R_8 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each R_9 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -C(halo)$_3$, -CH(halo)$_2$, ~~or~~ -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_{11} is independently -CN, -OH, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -halo, -N_3, -NO_2, -$N(R_7)_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2;

m is 0 or 1;

o is an integer ranging from 0 to 4;

q is an integer ranging from 0 to 6;

r is an integer ranging from 0 to 5;

s is an integer ranging from 0 to 4; and

t is an integer ranging from 0 to 2.

89. (currently amended) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88 and a pharmaceutically acceptable carrier or excipient.

90. (currently amended) A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88.

91. (currently amended) A method for treating urinary incontinence in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88.

92. (currently amended) A method for treating an ulcer in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88.

93. (currently amended) A method for treating irritable-bowel syndrome in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88.

94. (currently amended) A method for treating inflammatory-bowel disease in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88.

95. (currently amended) A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88.

96. (currently amended) A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88.

97. Canceled

98. Canceled

99. (currently amended) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88 and a pharmaceutically acceptable carrier or excipient.

100. (currently amended) A compound of formula (V):



(V)

or a pharmaceutically acceptable salt thereof, wherein:

Ar_2 is



R_1 is -H, -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each R_2 is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$;

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, -NO_2, or -NH_2;

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_5 is independently -CN, -OH, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -halo, -N_3, -NO_2, -$N(R_7)_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_6 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_7 is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each R_8 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each R_9 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -C(halo)$_3$, -CH(halo)$_2$, ~~or~~ -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_{11} is independently -CN, -OH, -$(C_1$-$C_6)$alkyl, -$(C_2$-$C_6)$alkenyl, -$(C_2$-$C_6)$alkynyl, -halo, -N_3, -NO_2, -$N(R_7)_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2;

m is 0 or 1;

o is an integer ranging from 0 to 4;

q is an integer ranging from 0 to 6;

r is an integer ranging from 0 to 5;

s is an integer ranging from 0 to 4; and

t is an integer ranging from 0 to 2.

101. (currently amended) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100 and a pharmaceutically acceptable carrier or excipient.

102. (currently amended) A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100.

103. (currently amended) A method for treating urinary incontinence in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100.

104. (currently amended) A method for treating an ulcer in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100.

105. (currently amended) A method for treating irritable-bowel syndrome in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100.

106. (currently amended) A method for treating inflammatory-bowel disease in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100.

107. (currently amended) A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100.

108. (currently amended) A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100.

109. Canceled

110. Canceled

111. (currently amended) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100 and a pharmaceutically acceptable carrier or excipient.

112. (original) The compound of claim 1, wherein:

n is 0;

m is 1;

R_3 is $-CH_3$;

R_1 is -halo; and

R_4 is phenyl.

113. (original) The compound of claim 112, wherein the R_4 phenyl is unsubstituted.

114. (original) The compound of claim 112, wherein the R_4 phenyl is substituted at the 4-position.

115. (original) The compound of claim 114, wherein the R_4 phenyl is substituted with a $-(C_1-C_6)$ alkyl group.

116. (original) The compound of claim 115, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

117. (original) The compound of claim 115, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

118. (currently amended) The compound of claim 114, wherein the $\underline{R_4}$ phenyl is substituted with a -CF_3 group.

119. (currently amended) The compound of claim 114, wherein the $\underline{R_4}$ phenyl is substituted with a -OCF_3 group.

120. (original) The compound of claim 112, wherein R_1 is -Cl.

121. (original) The compound of claim 120, wherein the R_4 phenyl is unsubstituted.

122. (original) The compound of claim 120, wherein the R_4 phenyl is substituted at the 4-position.

123. (original) The compound of claim 122, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

124. (original) The compound of claim 123, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

125. (original) The compound of claim 123, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

126. (currently amended) The compound of claim 122, wherein the $\underline{R_4}$ phenyl is substituted with a -CF_3 group.

127. (currently amended) The compound of claim 122, wherein the $\underline{R_4}$ phenyl is substituted with a -OCF_3 group.

128. (original) The compound of claim 112, wherein R_1 is -F.

129. (original) The compound of claim 128, wherein the R_4 phenyl is unsubstituted.

130. (original) The compound of claim 128, wherein the R_4 phenyl is substituted at the 4-position.

131. (original) The compound of claim 130, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

132. (original) The compound of claim 131, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

133. (original) The compound of claim 131, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

134. (currently amended) The compound of claim 130, wherein the $\underline{R_4}$ phenyl is substituted with a $-CF_3$ group.

135. (currently amended) The compound of claim 130, wherein the $\underline{R_4}$ phenyl is substituted with a $-OCF_3$ group.

136. (original) The compound of claim 1, wherein:

n is 0;

m is 1;

R_3 is $-CH_3$;

R_1 is $-CH_3$; and

R_4 is phenyl.

137. (original) The compound of claim 136, wherein the R_4 phenyl is unsubstituted.

138. (original) The compound of claim 136, wherein the R_4 phenyl is substituted at the 4-position.

139. (original) The compound of claim 138, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

140. (original) The compound of claim 139, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

141. (original) The compound of claim 139, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

142. (currently amended) The compound of claim 138, wherein the $\underline{R_4}$ phenyl is substituted with a $-CF_3$ group.

143. (currently amended) The compound of claim 138, wherein the $\underline{R_4}$ phenyl is substituted with a $-OCF_3$ group.

144. (original) The compound of claim 21, wherein:

n is 0;

m is 1;

R_3 is $-CH_3$;

R_1 is -halo; and

R_4 is phenyl.

145. (original) The compound of claim 144, wherein the R_4 phenyl is unsubstituted.

146. (original) The compound of claim 144, wherein the R_4 phenyl is substituted at the 4-position.

147. (original) The compound of claim 146, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

148. (original) The compound of claim 147, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

149. (original) The compound of claim 147, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

150. (currently amended) The compound of claim 146, wherein the $\underline{R_4}$ phenyl is substituted with a -CF_3 group.

151. (currently amended) The compound of claim 146, wherein the $\underline{R_4}$ phenyl is substituted with a -OCF_3 group.

152. (original) The compound of claim 144, wherein R_1 is -Cl.

153. (original) The compound of claim 152, wherein the R_4 phenyl is unsubstituted.

154. (original) The compound of claim 152, wherein the R_4 phenyl is substituted at the 4-position.

155. (original) The compound of claim 154, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

156. (original) The compound of claim 155, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

157. (original) The compound of claim 155, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

158. (currently amended) The compound of claim 154, wherein the $\underline{R_4}$ phenyl is substituted with a -CF_3 group.

159. (currently amended) The compound of claim 154, wherein the $\underline{R_4}$ phenyl is substituted with a -OCF_3 group.

160. (original) The compound of claim 144, wherein R_1 is -F.

161. (original) The compound of claim 160, wherein the R_4 phenyl is unsubstituted.

162. (original) The compound of claim 160, wherein the R_4 phenyl is substituted at the 4-position.

163. (original) The compound of claim 162, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

164. (original) The compound of claim 163, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

165. (original) The compound of claim 163, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

166. (currently amended) The compound of claim 162, wherein the $\underline{R_4}$ phenyl is substituted with a $-CF_3$ group.

167. (currently amended) The compound of claim 162, wherein the $\underline{R_4}$ phenyl is substituted with a $-OCF_3$ group.

168. (original) The compound of claim 21, wherein:

n is 0;

m is 1;

R_1 is $-CH_3$; and

R_4 is phenyl.

169. (original) The compound of claim 168, wherein the R_4 phenyl is unsubstituted.

170. (original) The compound of claim 168, wherein the R_4 phenyl is substituted at the 4-position.

171. (original) The compound of claim 170, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

172. (original) The compound of claim 171, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

173. (original) The compound of claim 171, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

174. (currently amended) The compound of claim 170, wherein the $\underline{R_4}$ phenyl is substituted with a -CF_3 group.

175. (currently amended) The compound of claim 170, wherein the $\underline{R_4}$ phenyl is substituted with a -OCF_3 group.

176. (original) The compound of claim 42, wherein:

n is 0;

m is 1;

R_3 is -CH_3;

R_1 is -halo; and

R_4 is phenyl.

177. (original) The compound of claim 176, wherein the R_4 phenyl is unsubstituted.

178. (original) The compound of claim 176, wherein the R_4 phenyl is substituted at the 4-position.

179. (original) The compound of claim 178, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

180. (original) The compound of claim 179, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

181. (original) The compound of claim 179, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

182. (currently amended) The compound of claim 178, wherein the $\underline{R_4}$ phenyl is substituted with a $-CF_3$ group.

183. (currently amended) The compound of claim 178, wherein the $\underline{R_4}$ phenyl is substituted with a $-OCF_3$ group.

184. (original) The compound of claim 176, wherein R_1 is -Cl.

185. (original) The compound of claim 184, wherein the R_4 phenyl is unsubstituted.

186. (original) The compound of claim 184, wherein the R_4 phenyl is substituted at the 4-position.

187. (original) The compound of claim 186, wherein the R_4 phenyl is substituted with a $-(C_1-C_6)$ alkyl group.

188. (original) The compound of claim 187, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.

189. (original) The compound of claim 187, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.

190. (currently amended) The compound of claim 186, wherein the $\underline{R_4}$ phenyl is substituted with a $-CF_3$ group.

191. (currently amended) The compound of claim 186, wherein the $\underline{R_4}$ phenyl is substituted with a $-OCF_3$ group.

192. (original) The compound of claim 176, wherein R_1 is -F.

193. (original) The compound of claim 192, wherein the R_4 phenyl is unsubstituted.

194. (original) The compound of claim 192, wherein the R_4 phenyl is substituted at the 4-position.

195. (original) The compound of claim 194, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

196. (original) The compound of claim 195, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

197. (original) The compound of claim 195, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

198. (currently amended) The compound of claim 194, wherein the $\underline{R_4}$ phenyl is substituted with a $-CF_3$ group.

199. (currently amended) The compound of claim 194, wherein the $\underline{R_4}$ phenyl is substituted with a $-OCF_3$ group.

200. (original) The compound of claim 42, wherein:

n is 0;

m is 1;

R_3 is $-CH_3$;

R_1 is $-CH_3$; and

R_4 is phenyl.

201. (original) The compound of claim 200, wherein the R_4 phenyl is unsubstituted.

202. (original) The compound of claim 200, wherein the R_4 phenyl is substituted at the 4-position.

203. (original) The compound of claim 202, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

204. (original) The compound of claim 203, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

205. (original) The compound of claim 203, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

206. (currently amended) The compound of claim 202, wherein the $\underline{R_4}$ phenyl is substituted with a -CF_3 group.

207. (currently amended) The compound of claim 202, wherein the $\underline{R_4}$ phenyl is substituted with a -OCF_3 group.